5AM Ventures reposted this
Today we reached another exciting clinical milestone in our journey to deliver a paradigm shift in the treatment of chronic inflammatory diseases, announcing positive data from a Phase Ib/IIa #cardiovascular risk study of our lead brain-penetrant #NLRP3 #inflammasone inhibitor candidate, NT-0796. The trial met its primary endpoint, demonstrating a highly statistically significant and rapid reduction of C-reactive protein (CRP), a key biomarker of chronic #cardiometabolic inflammatory diseases, in inflamed obese subjects dosed with NT-0796 compared to placebo. The study also saw reductions in body weight, the most pronounced among high-risk subgroups, supporting the anti-obesity potential of the molecule. Preparations are now underway for a Phase II #obesity study alongside other Phase IIa studies in additional cardiometabolic diseases and #ParkinsonsDisease. Learn more: https://bit.ly/4aYdBPR #NeuroInflammation #DrugDiscovery #Biotech
Congratulations to the whole NodThera team!
Congrats Alison Strutt & Alan Watt!
great news
Congrats!
Biopharmaceutical R&D Executive | Chief Medical Officer
2moFantastic news for the CV community as well as the NLRP3 community. Congratulations to the Nodthera team for leading the way.